Abstract
To study the effect of endostar on the expression of hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF) and radiosensitization, the changes of A549 cells treated by endostar, radiotherapy and radiotherapy plus endostar were checked by flow cytometry (FCM), methyl thiazolyl tetrazolium (MTT), hoechst staining, and enzyme linked immunosorbent assay (ELISA). The results showed that endostar could block cell periods of A549 and stopped the cell cycle at G2/M and S periods. Cell growth inhibiting and apoptotic rate in the combination group were higher than those in other groups. Meanwhile, the levels of HIF-1 and VEGF expression in the combination group were lower than those of other groups. It suggested that endostar significantly sensitizes the function of radiation in A549 cells by arresting the cell cycle at stage of G2/M and S, increasing the cell growth inhibiting and the apoptotic rate, down-regulating the expression of HIF-1 and VEGF.
Similar content being viewed by others
References
Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff GA, Sukhatme VP, Kufe DW, Weichselbaum RR (1998) Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394(6690):287–291
Oehler-Jänne C, Jochum W, Riesterer O, Broggini-Tenzer A, Caravatti G, Vuong V, Pruschy M (2007) Hypoxia modulation and radiosensitization by the novel dual EGFR and VEGFR inhibitor AEE788 in spontaneous and related allograft tumor models. Mol Cancer Ther 6(9):2496–2504
Ma BB, Bristow RG, Kim J, Siu LL (2003) Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 21(14):2760–2776
Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, Huber PE (2003) SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63(13):3755–3763
Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD (2001) Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61(1):39–44
Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, Hallahan DE (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61(6):2413–2419
Lee CG, Heijn M, di-Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60(19):5565–5570
Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92(12):5510–5514
Bruick RK, McKnight SL (2001) A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294(5545):1337–1340
Chu SH, Feng DF, Ma YB, Zhu ZA, Zhang H, Qiu JH (2009) Stabilization of hepatocyte growth factor mRNA by hypoxia-inducible factor 1. Mol Biol Rep 36(7):1967–1975
Yanyan C, Guoxian Q, Yang G, Leting W (2008) Mechanism of hypoxia-induced factor 1alpha expression in endothelial cells of the human umbilical vein and its induction of apoptosis. Mol Biol Rep 35(3):285–290
Semenza GL (2009) Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology 24(2):97–106
Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16(9):4604–4613
Ferrara N, Davis ST (1997) The biology of vascular endothelial growth factor. Endocr Rev 18(1):4–25
Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT, Yang PC (2000) Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 89(6):475–483
Bremnes RM, Camps C, Sirera R (2006) Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 51(2):143–158
Carrillo de Santa Pau E, Arias FC, Caso Peláez E, Muñoz Molina GM, Sánchez Hernández I, Muguruza Trueba I, Moreno Balsalobre R, Sacristán López S, Gómez Pinillos A, del Val Toledo L, Obo M (2009) Prognostic Significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with non small cell lung cancer. Cancer 115(8):1701–1712
Teng Y, Cui H, Yang M, Song H, Zhang Q, Su Y, Zheng J (2009) Protective effect of puerarin on diabetic retinopathy in rats. Mol Biol Rep 36(5):1129–1133
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin.An endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277–285
Kisker O, Becker CM, Prox D, Fannon M, D’Amato R, Flynn E, Fogler WE, Sim BK, Allred EN, Pirie-Shepherd SR, Folkman J (2001) Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 61(20):7669–7674
Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, Tanabe KK (1999) Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59(24):6251–6256
Ling Y, Yang Y, Lu N, You Q (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogeni blocking VEGF - induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361(1):79–84
Hong L, Sun H, Lv X, Yang D, Zhang J, Shi Y (2010) Expression of periostin in the serum of NSCLC and its function on proliferation and migration of human l ung adenocarcinoma cell line (A549) in vitro. Mol Biol Rep 37(5):2285–2293
Liu H, Zhang T, Wu B, Huang J, Zhou Y, Zhu J (2009) Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells. Mol Biol Rep 36(8):2099–2109
Shi W, Teschendorf C, Muzyczka N, Siemann DW (2003) Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 66(1):1–9
Wu DS, Wu CM, Huang TH, Xie QD (2008) Combined effects of radiotherapy and endostatin gene therapy in melanoma tumor model. Radiat Environ Biophys 47(2):285–291
Luo X, Slater JM, Gridley DS (2005) Enhancement of radiation effects by pX-LG-mEndo in lung carcinoma model. Int J Radiat Oncol Biol Phys 63(2):553–564
Wen QL, Meng MB, Yang B, Tu LL, Jia L, Zhou L, Xu Y, Lu Y (2009) Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice. Cancer Sci 100(8):1510–1519
Wu H, Deng J, Yu SY, Wang X, Chen Y (2010) The Inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms. J Huazhong Univ Sci Technol Med Sci 30(1):108–112
Zhen YY, Zhao Y, Liu F, Zhang YD, Wang JJ (2010) The radiosensitization effects of endostar on human lung squamous cancer cells H-520. Cancer Cell Int 24:17–26
Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, Inoue M, Hiraoka M (2007) Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26(54):7508–7516
Pore N, Gupta AK, Cerniglia GJ, Jiang Z, Bernhard EJ, Evans SM, Koch CJ, Hahn SM, Maity A (2006) Nelfinavir down-regulates hypoxia-inducible factor 1 alpha and VEGF expression and increases tumor oxygenation: implication for radiotherapy. Cancer Res 66(18):9252–9259
Acknowledgements
This work was supported by the key Program of National Natural Science Foundation of China (30970860).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, L., Ge, W., Hu, K. et al. Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells. Mol Biol Rep 39, 89–95 (2012). https://doi.org/10.1007/s11033-011-0713-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-011-0713-6